{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:10:19Z","timestamp":1776355819615,"version":"3.51.2"},"reference-count":64,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Amoxicillin is commonly used to treat erythema migrans in the first stage of Lyme disease in children, with a recommended dose of 50 mg\/kg\/day, administered three times a day (q8h). This model\u2010based simulation study aimed to determine whether splitting the same daily dose into two administrations (q12h) would provide comparable drug exposure. A pharmacokinetic model suitable for a pediatric population (age: 1 month to 18 years, weight: 4\u201080 kg) was selected through a literature review. Simulations were performed with 15,000 virtual patients receiving 16.67 mg\/kg\/dose q8h, 25 mg\/kg\/dose q12h, or other q12h dosing variations. The target therapeutic level was defined by the percentage of time that the unbound drug concentration remained above the minimum inhibitory concentration (% fT &gt; MIC) specific to <jats:italic>Borrelia burgdorferi<\/jats:italic>, with MICs of 0.06, 0.25, 1, 2, and 4 mg\/L, requiring at least 40% and 50% of time for effective treatment. Probability of target attainment (PTA) was considered acceptable if it exceeded 50%, allowing for comparison of dosing schedules. Results indicated that the 50 mg\/kg\/day divided q12h regimen provided similar drug exposure to the q8h regimen for MICs below 2 mg\/L (PTAs &gt;50%). For a MIC of 2 mg\/L, PTA was achieved with a higher dose of 30 mg\/kg\/dose q12h. However, for a MIC of 4 mg\/L, the PTA criterion was not met. These findings suggest that a twice\u2010daily dosing of 25 mg\/kg\/dose provides comparable bactericidal activity to the thrice\u2010daily regimen for MICs between 0.06 and 1 mg\/L. This simplified regimen may improve adherence and treatment implementation in children.<\/jats:p>","DOI":"10.1002\/jcph.6190","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T08:53:14Z","timestamp":1737967994000},"page":"742-750","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dose Evaluation and Optimization of Amoxicillin in Children Treated for Lyme Disease"],"prefix":"10.1002","volume":"65","author":[{"given":"Anne","family":"Ravix","sequence":"first","affiliation":[{"name":"Center for Research and Innovation in Clinical Pharmaceutical Sciences Lausanne University Hospital and University of Lausanne  Lausanne Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6254-5207","authenticated-orcid":false,"given":"Verena","family":"Gotta","sequence":"additional","affiliation":[{"name":"Division of Pediatric Pharmacology and Pharmacometrics University of Basel Children's Hospital  Basel Switzerland"},{"name":"SwissPedDose\/SwissPedNet Collaboration Expert Team  Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-1228","authenticated-orcid":false,"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[{"name":"Division of Pediatric Pharmacology and Pharmacometrics University of Basel Children's Hospital  Basel Switzerland"},{"name":"SwissPedDose\/SwissPedNet Collaboration Expert Team  Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Berger","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology University Children's Hospital Zurich  Zurich Switzerland"},{"name":"SwissPedDose  Z\u00fcrich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Glauser","sequence":"additional","affiliation":[{"name":"SwissPedDose  Z\u00fcrich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Paioni","sequence":"additional","affiliation":[{"name":"SwissPedDose\/SwissPedNet Collaboration Expert Team  Zurich Switzerland"},{"name":"Division of Infectious Diseases and Hospital Epidemiology University Children's Hospital Zurich  Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation in Clinical Pharmaceutical Sciences Lausanne University Hospital and University of Lausanne  Lausanne Switzerland"},{"name":"SwissPedDose\/SwissPedNet Collaboration Expert Team  Zurich Switzerland"},{"name":"School of Pharmaceutical Sciences University of Geneva University of Lausanne  Geneva Switzerland"},{"name":"Institute of Pharmaceutical Sciences of Western Switzerland University of Geneva University of Lausanne  Geneva &amp; Lausanne Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-9317","authenticated-orcid":false,"given":"Monia","family":"Guidi","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation in Clinical Pharmaceutical Sciences Lausanne University Hospital and University of Lausanne  Lausanne Switzerland"},{"name":"Institute of Pharmaceutical Sciences of Western Switzerland University of Geneva University of Lausanne  Geneva &amp; Lausanne Switzerland"},{"name":"Service of Clinical Pharmacology Lausanne University Hospital and University of Lausanne  Lausanne Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Office f\u00e9d\u00e9ral de la sant\u00e9 publique (OFSP).Borr\u00e9liose\/Maladie de Lyme. Accessed December 12 2021.https:\/\/www.bag.admin.ch\/bag\/fr\/home\/krankheiten\/krankheiten\u2010im\u2010ueberblick\/borreliose\u2010lyme\u2010krankheit.html"},{"key":"e_1_2_8_3_1","article-title":"Borr\u00e9liose de Lyme 1\u00e8re partie : \u00e9pid\u00e9miologie et diagnostic","author":"Weber R","journal-title":"Rev Med Suisse"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-007744"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/508667"},{"key":"e_1_2_8_6_1","volume-title":"Amoxicillin Sandoz","author":"Compendium"},{"key":"e_1_2_8_7_1","volume-title":"Red Book 2018: Report of the Committee on Infectious Diseases. E\u2010version","author":"Long","year":"2018"},{"key":"e_1_2_8_8_1","unstructured":"UpToDate.Amoxicillin: Pediatric drug information. Accessed December 20 2021.https:\/\/www.uptodate.com"},{"key":"e_1_2_8_9_1","volume-title":"Nelson's Pediatric Antimicrobial Therapy. E\u2010version","author":"Bradley JS","year":"2018"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2019.05.001"},{"key":"e_1_2_8_11_1","article-title":"Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society","volume":"15","author":"Hofmann H","year":"2017","journal-title":"Ger Med Sci"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1215"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.940900"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80109-0"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116207"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf046"},{"issue":"5","key":"e_1_2_8_17_1","first-page":"793","article-title":"Promoting medication adherence in children","volume":"74","author":"Gardiner P","year":"2006","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(05)70459-4"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.997-1001.2003"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku070"},{"issue":"3","key":"e_1_2_8_21_1","first-page":"195","article-title":"In vitro efficacy of antibiotics against different Borrelia isolates","volume":"68","author":"Veinovi\u0107 G","year":"2021","journal-title":"Acta Microbiol Immunol Hung"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.11.016"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-006-0693-z"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00864-15"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02013102"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.169"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1853"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-318676"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2009.06.008"},{"key":"e_1_2_8_31_1","volume-title":"Amoxicillin \u2010 Labelling information","author":"Food and drug administration (FDA)"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0236-8"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11091190"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.2.199"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.11.028"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.11.1.132"},{"key":"e_1_2_8_37_1","unstructured":"RohatagiA.WebPlotDigitizer. Accessed July 12 2022.https:\/\/automeris.io\/WebPlotDigitizer\/"},{"key":"e_1_2_8_38_1","volume-title":"NONMEM 7.4 users guides; (1989\u20102018)","author":"Beal SL"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/children9121995"},{"key":"e_1_2_8_40_1","volume-title":"Swiss society of paediatrics","year":"2011"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-288"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318180fe62"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1198-743x.2001.00295.x"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(96)00162-9"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.01030.x"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17228"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1752"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01368-15"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa368"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00505-18"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw226"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt240"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab337"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.02.007"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.3109\/02813438609014831"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0659-0"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23574"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000543"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12385"},{"key":"e_1_2_8_61_1","unstructured":"SwissPedDose.Amoxicillin. Accessed August 10 2023.https:\/\/db.swisspeddose.ch\/fr\/search\/?_search_fr=amoxic"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000942"},{"key":"e_1_2_8_63_1","volume-title":"General clinical pharmacology considerations for pediatric studies of drugs, including biological products","author":"Food and Drug Administration"},{"key":"e_1_2_8_64_1","volume-title":"Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population","author":"European Medicines Agency"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.2165\/11593210-000000000-00000"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.6190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:54:40Z","timestamp":1748364880000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.6190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/jcph.6190"],"URL":"https:\/\/doi.org\/10.1002\/jcph.6190","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"2024-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}